These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 23389808)
1. Effect of sera from seronegative myasthenia gravis patients on neuromuscular junctions. Sato R; Imamoto S; Utsnomiya I; Chiba T; Taguchi K; Abe K; Tanaka K; Miyatake T Neurol Sci; 2013 Oct; 34(10):1735-44. PubMed ID: 23389808 [TBL] [Abstract][Full Text] [Related]
2. [Clinical features of myasthenia related with autoantibodies to muscle specific tyrosine kinase (MuSK)]. Sanadze AG; Sidnev DV; Karganov MIu Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):72-6. PubMed ID: 21311492 [TBL] [Abstract][Full Text] [Related]
3. [Clinical and electrophysiological peculiarities of seronegative myasthenia]. Shcherbakova NI; Sanadze AG; Sidnev DV; Rudnichenko VA Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(3):4-10. PubMed ID: 18427534 [TBL] [Abstract][Full Text] [Related]
4. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395 [TBL] [Abstract][Full Text] [Related]
5. Anti-p110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement. Scuderi F; Marino M; Colonna L; Mannella F; Evoli A; Provenzano C; Bartoccioni E Lab Invest; 2002 Sep; 82(9):1139-46. PubMed ID: 12218074 [TBL] [Abstract][Full Text] [Related]
7. IgG from "seronegative" myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor. Blaes F; Beeson D; Plested P; Lang B; Vincent A Ann Neurol; 2000 Apr; 47(4):504-10. PubMed ID: 10762162 [TBL] [Abstract][Full Text] [Related]
8. The effectiveness of thymectomy on seronegative generalized myasthenia gravis: comparing with seropositive cases. Yuan HK; Huang BS; Kung SY; Kao KP Acta Neurol Scand; 2007 Mar; 115(3):181-4. PubMed ID: 17295713 [TBL] [Abstract][Full Text] [Related]
14. Effect of sera from myasthenia gravis patients and of alpha-bungarotoxin on acetylcholinesterase during in vitro neuromuscular synaptogenesis. de la Porte S; Ragueh F; Eymard B; Courbin P; Chapron J; Koenig J J Neurol Sci; 1993 Jul; 117(1-2):92-102. PubMed ID: 8410074 [TBL] [Abstract][Full Text] [Related]
15. Modulation of acetylcholine receptor expression in seronegative myasthenia gravis. Poea S; Guyon T; Bidault J; Bruand C; Mouly V; Berrih-Aknin S Ann Neurol; 2000 Nov; 48(5):696-705. PubMed ID: 11079532 [TBL] [Abstract][Full Text] [Related]
16. Nature and Action of Antibodies in Myasthenia Gravis. Ruff RL; Lisak RP Neurol Clin; 2018 May; 36(2):275-291. PubMed ID: 29655450 [TBL] [Abstract][Full Text] [Related]
17. Acetylcholine receptor antibodies in myasthenia gravis are associated with greater risk of diabetes and thyroid disease. Toth C; McDonald D; Oger J; Brownell K Acta Neurol Scand; 2006 Aug; 114(2):124-32. PubMed ID: 16867036 [TBL] [Abstract][Full Text] [Related]
19. Serological and clinical features of patients with myasthenia gravis in north Indian population. Suhail H; Subbiah V; Singh S; Behari M Int J Neurosci; 2010 Feb; 120(2):115-9. PubMed ID: 20199203 [TBL] [Abstract][Full Text] [Related]
20. A myasthenia gravis plasma immunoglobulin reduces miniature endplate potentials at human endplates in vitro. Burges J; Wray DW; Pizzighella S; Hall Z; Vincent A Muscle Nerve; 1990 May; 13(5):407-13. PubMed ID: 2345558 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]